Relating neurosteroid modulation of inhibitory neurotransmission to behaviour
© 2021 British Society for Neuroendocrinology..
Studies in the 1980s revealed endogenous metabolites of progesterone and deoxycorticosterone to be potent, efficacious, positive allosteric modulators (PAMs) of the GABAA receptor (GABAA R). The discovery that such steroids are locally synthesised in the central nervous system (CNS) promoted the thesis that neural inhibition in the CNS may be "fine-tuned" by these neurosteroids to influence behaviour. In preclinical studies, these neurosteroids exhibited anxiolytic, anticonvulsant, analgesic and sedative properties and, at relatively high doses, induced a state of general anaesthesia, a profile consistent with their interaction with GABAA Rs. However, realising the therapeutic potential of either endogenous neurosteroids or synthetic "neuroactive" steroids has proven challenging. Recent approval by the Food and Drug Administration of the use of allopregnanolone (brexanolone) to treat postpartum depression has rekindled enthusiasm for exploring their potential as new medicines. Although neurosteroids are selective for GABAA Rs, they exhibit little or no selectivity across the many GABAA R subtypes. Nevertheless, a relatively minor population of receptors incorporating the δ-subunit (δ-GABAA Rs) appears to be an important contributor to their behavioural effects. Here, we consider how neurosteroids acting upon GABAA Rs influence neuronal signalling, as well as how such effects may acutely and persistently influence behaviour, and explore the case for developing selective PAMs of δ-GABAA R subtypes for the treatment of psychiatric disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal of neuroendocrinology - 34(2022), 2 vom: 11. Feb., Seite e13045 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Belelli, Delia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
56-12-2 |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 19.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jne.13045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331855860 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331855860 | ||
| 003 | DE-627 | ||
| 005 | 20231225214406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jne.13045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331855860 | ||
| 035 | |a (NLM)34644812 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Belelli, Delia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relating neurosteroid modulation of inhibitory neurotransmission to behaviour |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 British Society for Neuroendocrinology. | ||
| 520 | |a Studies in the 1980s revealed endogenous metabolites of progesterone and deoxycorticosterone to be potent, efficacious, positive allosteric modulators (PAMs) of the GABAA receptor (GABAA R). The discovery that such steroids are locally synthesised in the central nervous system (CNS) promoted the thesis that neural inhibition in the CNS may be "fine-tuned" by these neurosteroids to influence behaviour. In preclinical studies, these neurosteroids exhibited anxiolytic, anticonvulsant, analgesic and sedative properties and, at relatively high doses, induced a state of general anaesthesia, a profile consistent with their interaction with GABAA Rs. However, realising the therapeutic potential of either endogenous neurosteroids or synthetic "neuroactive" steroids has proven challenging. Recent approval by the Food and Drug Administration of the use of allopregnanolone (brexanolone) to treat postpartum depression has rekindled enthusiasm for exploring their potential as new medicines. Although neurosteroids are selective for GABAA Rs, they exhibit little or no selectivity across the many GABAA R subtypes. Nevertheless, a relatively minor population of receptors incorporating the δ-subunit (δ-GABAA Rs) appears to be an important contributor to their behavioural effects. Here, we consider how neurosteroids acting upon GABAA Rs influence neuronal signalling, as well as how such effects may acutely and persistently influence behaviour, and explore the case for developing selective PAMs of δ-GABAA R subtypes for the treatment of psychiatric disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a GABAA receptor | |
| 650 | 4 | |a allopregnanolone | |
| 650 | 4 | |a major depressive disorder | |
| 650 | 4 | |a neurosteroid | |
| 650 | 4 | |a postpartum depression | |
| 650 | 7 | |a Neurosteroids |2 NLM | |
| 650 | 7 | |a Receptors, GABA-A |2 NLM | |
| 650 | 7 | |a gamma-Aminobutyric Acid |2 NLM | |
| 650 | 7 | |a 56-12-2 |2 NLM | |
| 700 | 1 | |a Phillips, Grant D |e verfasserin |4 aut | |
| 700 | 1 | |a Atack, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Jeremy J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroendocrinology |d 1989 |g 34(2022), 2 vom: 11. Feb., Seite e13045 |w (DE-627)NLM07473041X |x 1365-2826 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2022 |g number:2 |g day:11 |g month:02 |g pages:e13045 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jne.13045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2022 |e 2 |b 11 |c 02 |h e13045 | ||